Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
Cohort B, which combined radiotherapy with CDX-301, poly-ICLC, and nivolumab, demonstrated encouraging clinical activity. Preexisting rather than treatment-induced immune activation was associated with clinical benefit across cohorts, highlighting the importance of baseline immune fitness.
Authors
- Kristin M. Shotts
- Jennifer Lata
- Timothy R. Howes (ORCID: https://orcid.org/0000-0002-0370-0200)
- Matthew D. Galsky (ORCID: https://orcid.org/0000-0001-7655-9378)
- Tibor Keler (ORCID: https://orcid.org/0000-0003-1757-4230)
- Sumit Kumar Subudhi (ORCID: https://orcid.org/0000-0001-5208-7732)
- Ute Dugan (ORCID: https://orcid.org/0009-0008-9408-2671)
- Kristopher Wentzel
- Jill O’Donnell-Tormey
- Julie N. Graff (ORCID: https://orcid.org/0000-0002-5708-2794)
- Christopher R. Cabanski (ORCID: https://orcid.org/0009-0007-9938-1331)
- Julie Densmore (ORCID: https://orcid.org/0009-0006-0191-1780)
- Nina Bhardwaj (ORCID: https://orcid.org/0000-0003-1865-4187)
- Silvia Boffo (ORCID: https://orcid.org/0000-0002-6352-160X)
- Theresa LaVallee (ORCID: https://orcid.org/0000-0002-1769-3195)
- Michael Yellin (ORCID: https://orcid.org/0000-0002-1164-7614)
- Richard Chen (ORCID: https://orcid.org/0000-0002-2842-4476)
- Jeffrey Skolnik (ORCID: https://orcid.org/0000-0002-0476-9453)
- Justin P. Fairchild (ORCID: https://orcid.org/0000-0002-4478-7146)
- Lawrence H. Fong (ORCID: https://orcid.org/0000-0002-6428-428X)
- Terence W. Friedlander (ORCID: https://orcid.org/0000-0002-3630-4941)
- Diane M. Da Silva (ORCID: https://orcid.org/0000-0001-7317-4886)
- Marko Spasic
- Karen A. Autio (ORCID: https://orcid.org/0000-0003-0720-0390)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Bristol-Myers Squibb (Germany) (DE)
- Oregon Health & Science University (US)
- Cancer Research Institute (US)
- University of California, San Francisco (US)
- Spencer Foundation (US)
- Fred Hutch Cancer Center (US)
- Bristol-Myers Squibb (United States) (US)
- Coherus BioSciences (United States) (US)
- Angeles Clinic and Research Institute (US)
- Parker Institute for Cancer Immunotherapy (US)
- Personalis (United States) (US)
- Tisch Hospital (US)
- Bristol-Myers Squibb (Sweden) (SE)
- Inovio Pharmaceuticals (United States) (US)
- VA Portland Health Care System (US)
- Celldex Therapeutics (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3693
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Cancer Research Institute
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Memorial Sloan-Kettering Cancer Center
- Celldex Therapeutics
- Parker Institute for Cancer Immunotherapy
- Seagen
- Natera
- Astellas Pharma
- National Institutes of Health
- Genentech